Rejuvenating Regenerative Medicine Regulation

Rejuvenating Regenerative Medicine Regulation By clarifying its position on the handling and therapeutic use of human cell–based products, the FDA has signaled its intention to regulate a broad swath of highly manipulated cellular materials as biologic drugs. This move is welcome, but more remains to be done.